Market capitalization | $270.18m |
Enterprise Value | $221.53m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 2,461.44 |
P/S ratio (TTM) P/S ratio | 3,002.00 |
P/B ratio (TTM) P/B ratio | 4.94 |
Revenue growth (TTM) Revenue growth | -71.52% |
Revenue (TTM) Revenue | $90.00k |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
3 Analysts have issued a Sera Prognostics Inc - Ordinary Shares Class A forecast:
3 Analysts have issued a Sera Prognostics Inc - Ordinary Shares Class A forecast:
Sep '24 |
+/-
%
|
||
Revenue | 0.09 0.09 |
73%
73%
|
|
Gross Profit | -0.94 -0.94 |
27%
27%
|
|
EBITDA | -35 -35 |
13%
13%
|
EBIT (Operating Income) EBIT | -36 -36 |
13%
13%
|
Net Profit | -32 -32 |
15%
15%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Sera Prognostics, Inc. engages in the provision of personalized diagnostics to predict and manage pregnancy complications. It focuses on developing blood tests to predict the risks of preterm birth, preeclampsia and other pregnancy complications. The company was founded by Steven W. Graves, Dennis Farrar and M. Sean Esplin in 2008 and is headquartered in Salt Lake City, UT.
Head office | United States |
CEO | Evguenia Lindgardt |
Employees | 57 |
Founded | 2008 |
Website | www.seraprognostics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.